Screening for Pulmonary Vascular Changes in Patients With Chronic Myeloproliferative Diseases
Goal of the study is to assess the frequency of pulmonary hypertension in patients with chronic myeloproliferative diseases. In each patient an echocardiography at rest will be performed. In patients without musculoskeletal disease an exercise test (spiroergometry) will be performed. Patients with elevated SPAP at rest or with reduced exercise capacity (peak VO2 < 65%) a right heart catheterization (RHC) will be recommended. Also patients with advanced NYHA functional class (III or IV) or with typical PH findings in electrocardiogram will be advised to undergo a RHC. Additionally for the evaluation of exercise capacity a 6 MWD will be performed.
This work- up of patients allows clinical and hemodynamic evaluation.
|Myeloproliferative Disorders Pulmonary Hypertension||Other: Echocardiography, spiroergometry, cardiac catheterization|
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Screening for Pulmonary Vascular Changes in Patients With Chronic Myeloproliferative Diseases|
- pulmonary arterial pressure [ Time Frame: at baseline ]
- change of pulmonary arterial pressure [ Time Frame: between baseline and after 6 months ]
Biospecimen Retention: Samples With DNA
Samples with DNA will be retained for later examinations at the Biobank, in case that the patient agrees (extra patient information).
The blood samples are taken only during routine tests.
|Study Start Date:||July 2012|
|Study Completion Date:||June 2015|
|Primary Completion Date:||June 2015 (Final data collection date for primary outcome measure)|
Echocardiography, spiroergometry, cardiac catheterization
Other: Echocardiography, spiroergometry, cardiac catheterization
patients with CMPD will undergo echocardiography, spiroergometry, and right heart catheterization, if indicated
Previous small studies and clinical cases have suggested a possible association between pulmonary hypertension (PH) and chronic myeloproliferative disorders (CMPD). MPD may cause PH through different mechanisms as: high cardiac output, asplenia, direct obstruction of pulmonary arteries by megakaryocytes, chronic thromboembolic endothelial pulmonary hypertension (CTEPH), porto-pulmonary hypertension (POPH). However, the exact prevalence of PH in this group of disorders is not known.
This study is designed to identify the pulmonary vascular changes and describe the prevalence of pulmonary hypertension (defined in this study as mean pulmonary arterial hypertension (mPAP) ≥25mmHg as assessed by right-heart catheterization (RHC) or systolic pulmonary arterial pressure (sPAP) ≥37mmHg (2.9 m/s) assessed by echocardiography.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01787162
|Medical University of Graz, Pulmonology|
|Graz, Austria, 8036|
|Principal Investigator:||Horst Olschewski, MD||Medical University of Graz|